Fenwick & West represented Gritstone Oncology, a next-generation personalized cancer immunotherapy company, in the intellectual property due diligence aspect of its initial public offering and its strategic collaboration with Bluebird Bio to research, develop and commercialize products for the treatment of cancer using cell therapy. More information about Gritstone’s strategic collaboration can be obtained from their press release.
The Fenwick team was led by intellectual property attorneys Michael Shuster and Kevin Kabler.